ChiCTR2100051569
结束
/
/
/
2021-09-27
/
/
新型冠状病毒肺炎(COVID-19)
Post COVID-19 pulmonary complications: a single center experience
Post COVID-19 pulmonary complications: a single center experience
46000
The current study aims to present a series of cases whom have developed short-term pulmonary complications after recovering from COVID-19.
连续入组
回顾性研究
No
N/A
Smart health tower
/
19
/
2021-01-05
2021-07-29
/
Those patients were included who were infected with SARS-CoV-2 and developed pulmonary symptoms in less than 6 months of recovery, or already had the symptoms during active infection but persisted even after recovery. These symptoms should be clearly related to COVID-19 infection.；
登录查看Known cases of lung cancer, tuberculosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and other chronic lung diseases were excluded from the study.；
登录查看Al-Jamhori teaching hospital
46000
精准药物2024-11-23
亚泰制药2024-11-23
昌郁医药2024-11-22
上海和誉生物医药科技有限公司2024-11-22
云顶新耀2024-11-22
金斯瑞生物2024-11-22
细胞与基因治疗领域2024-11-22
肝脏时间2024-11-22
医药笔记2024-11-22
生物安全情报网2024-11-22
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
